160 related articles for article (PubMed ID: 26211902)
21. In vitro and in vivo evaluation of drug-eluting microspheres designed for transarterial chemoembolization therapy.
Wang Y; Molin DG; Sevrin C; Grandfils C; van den Akker NM; Gagliardi M; Knetsch ML; Delhaas T; Koole LH
Int J Pharm; 2016 Apr; 503(1-2):150-62. PubMed ID: 26965198
[TBL] [Abstract][Full Text] [Related]
22. Biomacromolecule/lipid hybrid nanoparticles for controlled delivery of sorafenib in targeting hepatocellular carcinoma therapy.
Zhang J; Wang T; Mu S; Olerile LD; Yu X; Zhang N
Nanomedicine (Lond); 2017 Apr; 12(8):911-925. PubMed ID: 28339312
[TBL] [Abstract][Full Text] [Related]
23. Nanoassemblies Based on Supramolecular Complexes of Nonionic Amphiphilic Cyclodextrin and Sorafenib as Effective Weapons to Kill Human HCC Cells.
Bondì ML; Scala A; Sortino G; Amore E; Botto C; Azzolina A; Balasus D; Cervello M; Mazzaglia A
Biomacromolecules; 2015 Dec; 16(12):3784-91. PubMed ID: 26528591
[TBL] [Abstract][Full Text] [Related]
24. Development and evaluation of lipid nanoparticles for camptothecin delivery: a comparison of solid lipid nanoparticles, nanostructured lipid carriers, and lipid emulsion.
Huang ZR; Hua SC; Yang YL; Fang JY
Acta Pharmacol Sin; 2008 Sep; 29(9):1094-102. PubMed ID: 18718178
[TBL] [Abstract][Full Text] [Related]
25. A new topical formulation for psoriasis: development of methotrexate-loaded nanostructured lipid carriers.
Pinto MF; Moura CC; Nunes C; Segundo MA; Costa Lima SA; Reis S
Int J Pharm; 2014 Dec; 477(1-2):519-26. PubMed ID: 25445970
[TBL] [Abstract][Full Text] [Related]
26. Design, characterization, and in vitro cellular inhibition and uptake of optimized genistein-loaded NLC for the prevention of posterior capsular opacification using response surface methodology.
Zhang W; Li X; Ye T; Chen F; Sun X; Kong J; Yang X; Pan W; Li S
Int J Pharm; 2013 Sep; 454(1):354-66. PubMed ID: 23876384
[TBL] [Abstract][Full Text] [Related]
27. Delivery of retinoic acid to LNCap human prostate cancer cells using solid lipid nanoparticles.
Akanda MH; Rai R; Slipper IJ; Chowdhry BZ; Lamprou D; Getti G; Douroumis D
Int J Pharm; 2015 Sep; 493(1-2):161-71. PubMed ID: 26200751
[TBL] [Abstract][Full Text] [Related]
28. Fabrication of poly (butadiene-block-ethylene oxide) based amphiphilic polymersomes: An approach for improved oral pharmacokinetics of Sorafenib.
Khan MA; Ali S; Venkatraman SS; Sohail MF; Ovais M; Raza A
Int J Pharm; 2018 May; 542(1-2):196-204. PubMed ID: 29551745
[TBL] [Abstract][Full Text] [Related]
29. Entrapment of an EGFR inhibitor into nanostructured lipid carriers (NLC) improves its antitumor activity against human hepatocarcinoma cells.
Bondì ML; Azzolina A; Craparo EF; Botto C; Amore E; Giammona G; Cervello M
J Nanobiotechnology; 2014 May; 12():21. PubMed ID: 24886097
[TBL] [Abstract][Full Text] [Related]
30. Tamoxifen-loaded nanostructured lipid carrier as a drug delivery system: characterization, stability assessment and cytotoxicity.
How CW; Rasedee A; Manickam S; Rosli R
Colloids Surf B Biointerfaces; 2013 Dec; 112():393-9. PubMed ID: 24036474
[TBL] [Abstract][Full Text] [Related]
31. Second generation lipid nanoparticles (NLC) as an oral drug carrier for delivery of lercanidipine hydrochloride.
Ranpise NS; Korabu SS; Ghodake VN
Colloids Surf B Biointerfaces; 2014 Apr; 116():81-7. PubMed ID: 24445002
[TBL] [Abstract][Full Text] [Related]
32. Optimization of nanostructured lipid carriers loaded with methotrexate: A tool for inflammatory and cancer therapy.
Ferreira M; Chaves LL; Lima SA; Reis S
Int J Pharm; 2015 Aug; 492(1-2):65-72. PubMed ID: 26169145
[TBL] [Abstract][Full Text] [Related]
33. Preparation and characterization of nanostructured lipid carriers loaded traditional Chinese medicine, zedoary turmeric oil.
Zhao XL; Yang CR; Yang KL; Li KX; Hu HY; Chen DW
Drug Dev Ind Pharm; 2010 Jul; 36(7):773-80. PubMed ID: 20136496
[TBL] [Abstract][Full Text] [Related]
34. Galactosylated polymeric carriers for liver targeting of sorafenib.
Craparo EF; Sardo C; Serio R; Zizzo MG; Bondì ML; Giammona G; Cavallaro G
Int J Pharm; 2014 May; 466(1-2):172-80. PubMed ID: 24607205
[TBL] [Abstract][Full Text] [Related]
35. The use of lipid-coated nanodiamond to improve bioavailability and efficacy of sorafenib in resisting metastasis of gastric cancer.
Zhang Z; Niu B; Chen J; He X; Bao X; Zhu J; Yu H; Li Y
Biomaterials; 2014 May; 35(15):4565-72. PubMed ID: 24602567
[TBL] [Abstract][Full Text] [Related]
36. Structural investigations on nanoemulsions, solid lipid nanoparticles and nanostructured lipid carriers by cryo-field emission scanning electron microscopy and Raman spectroscopy.
Saupe A; Gordon KC; Rades T
Int J Pharm; 2006 May; 314(1):56-62. PubMed ID: 16574354
[TBL] [Abstract][Full Text] [Related]
37. Polyhydroxy surfactants for the formulation of lipid nanoparticles (SLN and NLC): effects on size, physical stability and particle matrix structure.
Kovacevic A; Savic S; Vuleta G; Müller RH; Keck CM
Int J Pharm; 2011 Mar; 406(1-2):163-72. PubMed ID: 21219990
[TBL] [Abstract][Full Text] [Related]
38. Preparation and characteristics of oridonin-loaded nanostructured lipid carriers as a controlled-release delivery system.
Dai W; Zhang D; Duan C; Jia L; Wang Y; Feng F; Zhang Q
J Microencapsul; 2010 May; 27(3):234-41. PubMed ID: 20113167
[TBL] [Abstract][Full Text] [Related]
39. The efficacy and safety of bufadienolides-loaded nanostructured lipid carriers.
Li F; Weng Y; Wang L; He H; Yang J; Tang X
Int J Pharm; 2010 Jun; 393(1-2):203-11. PubMed ID: 20385221
[TBL] [Abstract][Full Text] [Related]
40. Modification of oral absorption of oxyresveratrol using lipid based nanoparticles.
Sangsen Y; Wiwattanawongsa K; Likhitwitayawuid K; Sritularak B; Wiwattanapatapee R
Colloids Surf B Biointerfaces; 2015 Jul; 131():182-90. PubMed ID: 25988282
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
